Brief: Mustang Bio Says Data On Treatment With Lentiviral Viral Vector Gene Therapy Selected For Oral Presentation

Mustang Bio

03/05/2022 13:33

May 3 (Reuters) - Fortress Biotech Inc  FBIO.O :
    * MUSTANG BIO ANNOUNCES DATA ON TREATMENT WITH LENTIVIRAL
VIRAL
VECTOR GENE THERAPY FOR X-LINKED SEVERE COMBINED
IMMUNODEFICIENCY SELECTED FOR ORAL PRESENTATION AT AMERICAN
SOCIETY OF GENE & CELL THERAPY 25TH ANNUAL MEETING
    * MUSTANG BIO INC - SEVENTEEN OF 18 PATIENTS WITH FOLLOW-UP
GREATER THAN 6 MONTHS ACHIEVED ROBUST IMMUNE RECONSTITUTION
    * MUSTANG BIO INC - ALL 23 TREATED PATIENTS ARE ALIVE AND 20
PATIENTS WITH FOLLOW-UP GREATER THAN 4 MONTHS RECOVERED FROM
PRE-EXISTING INFECTIONS
    * MUSTANG BIO -  20 PATIENTS WITH A FOLLOW-UP >4 MONTHS ARE
OFF
PROTECTIVE ISOLATION AND PROPHYLACTIC ANTIMICROBIALS, AND HAVE
NORMAL GROWTH VELOCITY

Source text for Eikon:  ID:nGNX1N5jfM 
Further company coverage:  FBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))